Mnova Screen

Importance of the topic

Fragment based screening using NMR is a cornerstone technique in early drug discovery due to its ability to directly detect weak interactions between small fragments and protein targets with high sensitivity and low false positive rates. Automating this process accelerates hit identification and resource allocation in pharmaceutical and academic research.

Objectives and study overview

The main goal of Mnova Screen is to deliver a fully automated platform for fast and reliable detection of fragment hits in ligand-detected NMR experiments. The software aims to integrate pattern recognition algorithms, deconvolution methods, and standardized reporting to streamline fragment based drug discovery campaigns.

Methodology and instrumentation

Mnova Screen supports analysis of multiple NMR experiment types (STD, WaterLOGSY, T1ρ, CPMG) using either 1H or 19F nuclei. It employs pattern matching and spectral deconvolution to pick peaks, even in low signal-to-noise conditions. Batch processing is managed via a Master Data File in JSON format, automatically associating reference and screening spectra. The tool reads raw and processed data from major spectrometer vendors (Bruker, Varian/Agilent, JEOL) and exports metrics for downstream statistical analysis.

Main results and discussion

Through automated peak matching and intensity change detection, Mnova Screen classifies fragment signals as present, hits, or confirmed by crystallography. Specificity is assessed via competition experiments, identifying fragments that recover signal upon inhibitor addition. The results viewer allows rapid inspection of individual and stacked spectra, enhancing confidence in hit selection. Case studies demonstrate successful identification of 1H and 19F hits using CPMG and other experiments with reduced manual intervention.

Benefits and practical applications

• Versatile analysis across four NMR experiment types improves hit coverage and reduces false negatives.
• Deconvolution enhances detection of weak, overlapping signals, increasing accuracy.
• Seamless batch processing and standardized data organization accelerate workflow throughput.
• Integration with statistical packages enables flexible downstream analysis.
• Specificity testing via competition experiments helps prioritize high-quality leads.

Mnova Screen is well suited for pharmaceutical screening labs, academic structural biology groups, and CROs engaged in fragment-based screening by NMR.

Future trends and applications

Advances in AI-driven spectral analysis and cloud-based data pipelines are expected to further reduce processing times and improve hit validation. Integration with structural and computational methods will enable real-time druggability assessments. Extensions to other nuclei and spectroscopic techniques may widen the applicability of automated NMR screening.

Conclusion

Mnova Screen represents a comprehensive solution for automated fragment screening by NMR, combining robust pattern recognition, deconvolution, and batch processing to accelerate hit discovery. Its flexibility and integration capabilities make it a valuable tool for diverse research environments.